from December 5, 2022.
Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Board of Biocon Biologics.
Tambe served as deputy CEO of Biocon Biologics since March 2021, where he played an important role in supporting Chandavarkar steer the company towards sustainable growth. Both have also played an integral role in the Biocon Biologics’ acquisition of Viatris’ global biosimilars business for $3.34 billion and the strategic alliance with Serum Institute Life Sciences (SILS).
BBL said Tambe will lead BBL in realizing its goal of being a global biosimilars leader.
“I am extremely pleased that Shreehas is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition,” said Kiran Mazumdar-Shaw, executive chairperson, Biocon & Biocon Biologics.
“His demonstrated track record of business success, deep technical and operational expertise provide him with proven leadership capabilities to assume this role,” Mazumdar-Shaw added.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build and shape Biocon’s biosimilars business and spearheaded the Group’s strategic capital investments, including its first overseas facility in Malaysia. He has also been instrumental in securing regulatory approvals and enabling the successful launch of several of the Company’s biosimilar assets in global markets such as the U.S. and EU.
Tambe holds a masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences & Technology at the University of Pune.
